Shares of the leading hybrid ophthalmic pharmaceutical and medical technology company Avedro (NASDAQ: AVDR) rose by as much as 45% today on heavy volume, while fellow eye disease company Glaukos (NYSE ...

Providence Health Plan, Health New England, and Public Employees Health Plan Are Latest to Join Extensive List of Payers Covering Over 95% of Estimated Total U.S. Addressable Market for Progressive ...

WALTHAM, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro) today announced its schedule of scientific and educational programs focused on corneal cross-linking and ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Please provide your email address to receive an email when new articles are posted on . Avedro announced that 50 commercial insurance plans now cover its FDA-approved corneal cross-linking procedure, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Avedro Inc. has received $25 million in financing from ...

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has secured $25 million in ...

Avedro has had the brakes put on alternative applications of its KXL System by the FDA, which issued a complete response letter less than two weeks after the company received additional financing to ...

Avedro announced that it has resubmitted its New Drug Application (NDA) to the Food and Drug Administration (FDA) for riboflavin ophthalmic solution/KXL System for the treatment of progressive ...

Avedro Inc has received a complete response letter from the US Food and Drug Administration (FDA) regarding their new drug application (NDA) for riboflavin ophthalmic solution/KXL System to treat ...

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do ...

Shares of the leading hybrid ophthalmic pharmaceutical and medical technology company Avedro (NASDAQ: AVDR) rose by as much as 45% today on heavy volume, while fellow eye disease company Glaukos (NYSE ...